2014 has been a super year for investors in AstraZeneca (LSE: AZN) (NYSE: AZN.US). Shares in the pharmaceutical giant have risen by 24% since the turn of the year, which is far better than the performance of the FTSE 100 over the same time period.
The FTSE's second-biggest pharmaceuticals company AstraZeneca (LSE: AZN) (NYSE: AZN) has been in the news over the past year, with its share price having been boosted by the Pfizer bid attempt, to 4,573p today.
'Sell in May and don't come back until St. Ledger's day' is a well-known saying in investing circles. Indeed, data from recent decades seems to back it up: the stock market rarely embarks on a sustained summer rally and usually falls between May and ...
AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been providing investors with attractive dividend yields for years - those blockbuster drugs do cost a lot of money to being to market, but once they've gained approval, they can be cash cows for years to come.